The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Cell & Gene
    • Bioprocessing
    • Drug Delivery
    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Regulation & Standards
    • Small Molecules
    • Supply Chain
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • eBooks
    • Content Hubs
Subscribe
Subscribe
The Medicine Maker / Issues / 2021 / Feb / The Inhalation Advantage
Discovery & Development Formulation Drug Delivery Sponsored

The Inhalation Advantage

Faster and more affordable development of inhaled medicines

02/04/2021 1 min read

Sponsored By

Vectura

Share

Vectura has more than 20 years’ experience in helping customers bring inhaled medicines to the market, and integrates formulation, device and development capabilities to offer a broad range of services to accelerate inhaled products through the phases of drug development. Having expertise in product formulation and device development across a number of platforms offers customers both flexibility and continuity, forging true collaborative partnerships to combine the right drug with the right device.

The trend within the industry to find new uses for old drugs has increased, and might take a drug already approved for one indication, and find utility in another; or create a new formulation to allow administration via a different route for the same indication. Alternatively, an existing drug may have its product profile improved or altered, while keeping the same administration route. Either way, as well as providing advantages for patients, it can offer new intellectual property coverage, driving additional revenue for innovators with lower risk and faster entry to market.

Inhaled delivery offers opportunities for improved dosing, simpler, less invasive administration, enhanced patient adherence, and product lifecycle management. By repurposing known drugs and leveraging pre-existing drug safety data, manufacturers benefit from shorter, less costly and less risky development programs, which has been particularly relevant for accelerating the progression of COVID-19 products.

In a recent webinar, Geraldine Venthoye, Chief Scientific Officer and Executive Vice President, Product Development at Vectura, discusses the value of inhaled drug delivery, and how repurposing or repositioning a drug can represent a safer, faster and more affordable way to develop new products than de novo drug discovery and development.

Dr. Venthoye also reviews the recent interest in inhaled COVID-19 products, choosing devices for repurposed products, device selection for repurposed biologics, and mitigating the environmental impact of devices. The webinar is available at https://bit.ly/3pdBQTD

Newsletters

Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Recommended

Related Content

The Confidentiality Barrier to AI-Enabled Drug Development
Small Molecules Small Molecules Formulation
The Confidentiality Barrier to AI-Enabled Drug Development

July 27, 2026

3 min read

AI can help formulation teams better predict performance and allocate resources, but proprietary data protections remain a critical bottleneck

Why Drug Development Still Lacks Integration
Small Molecules Small Molecules Business & Trends
Why Drug Development Still Lacks Integration

July 21, 2026

4 min read

John McDermott reflects on why early drug development remains fragmented – and how integrated approaches may shorten timelines

In Vivo CAR T: A New Route to Treating Autoimmune Disease
Cell & Gene Drug Delivery Development & Clinical
In Vivo CAR T: A New Route to Treating Autoimmune Disease

July 13, 2026

6 min read

How targeted in vivo CAR T delivery could pave the way for autoimmune disease treatments

Reformulating the Future of Small Molecules
Small Molecules Drug Discovery Formulation
Reformulating the Future of Small Molecules

June 30, 2026

1 min read

A special collection of recent stories exploring oral dose innovation, API stability, nitrosamine testing, and the evolving science of small molecule medicines

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions: